A phase 1/phase 2 study to investigate safety, tolerability and efficacy with TG01/QS-21 vaccine administration in patients with confirmed KRAS or NRAS codon 12/13 mutation and high-risk smoldering multiple myeloma or multiple myeloma and evidence of measurable disease = 1 line of treatment.
Phase 1
Active, not recruiting
- Conditions
- multiple myelomaMedDRA version: 21.0Level: LLTClassification code: 10028228Term: Multiple myeloma Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10075894Term: Smoldering myeloma Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10028232Term: Multiple myeloma myelomatosis Class: 10029104Therapeutic area: Diseases [C] - Hemic and Lymphatic Diseases [C15]
- Registration Number
- CTIS2022-502275-39-00
- Lead Sponsor
- Oslo University Hospital Hf
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method